The point-of-care molecular diagnostics market is predicted to secure a valuation of US$ 4.4 billion in 2023 and is rising to US$ 11.1 billion by 2033. The market is estimated at a CAGR of 9.7% during the forecast period. Rising infectious and chronic diseases, such as cardiovascular, diabetes, and COVID-19, are increasing the adoption of point-of-care molecular diagnostics. The demand for point-of-care molecular diagnostics is further increasing due to delayed testing results and high costs. Moreover, point-of-care molecular diagnostics manufacturers are growing the market opportunities by increasing production in the global market.